Modulation of Amyloid-β1–40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · see citing works

Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease

the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234 · see citing works

Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · see citing works

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.

Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525 · see citing works

RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426 · see citing works

Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier

Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · see citing works

Antiinflammatory Properties of HDL

Barter, P. J., Nicholls, S., Rye, K.-A., Anantharamaiah, G. M., Navab, M., & Fogelman, A. M. (2004) · Circulation Research · doi:10.1161/01.res.0000146094.59640.13 · Cited by 1,394 · see citing works

Amyloid β-Protein Fibrillogenesis

Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., & Teplow, D. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25945 · Cited by 1,046 · see citing works

Cholesterol metabolism in the brain

Dietschy, J. M., & Turley, S. D. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200104000-00003 · Cited by 906 · see citing works

Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease

Bell, R. D., & Zloković, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 855 · see citing works

LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms

Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828 · see citing works

apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain

Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · see citing works

Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System

Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · see citing works

ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?

Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608 · see citing works

Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy

Greenberg, S. M., Rebeck, G., Vonsattel, J. P., Gómez-Isla, T., & Hyman, B. (1995) · Annals of Neurology · doi:10.1002/ana.410380219 · Cited by 508 · see citing works

Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.

Zlokovic, B. V., Martel, C. L., Matsubara, E., McComb, J. G., Zheng, G., McCluskey, R. T., Frangione, B., & Ghiso, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4229 · Cited by 430 · see citing works

Clearing amyloid through the blood-brain barrier

Zlokovic, B. V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02385.x · Cited by 336 · see citing works

Restoring Blood-Brain Barrier P-Glycoprotein Reduces Brain Amyloid-β in a Mouse Model of Alzheimer’s Disease

Hartz, A. M. S., Miller, D. S., & Bauer, B. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.061754 · Cited by 319 · see citing works

The cerebrospinal-fluid soluble form of Alzheimer's amyloid β is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex

Ghiso, J., Matsubara, E., Koudinov, A., Choi-Miura, N. H., Tomita, M., Wisniewski, T., & Frangione, B. (1993) · Biochemical Journal · doi:10.1042/bj2930027 · Cited by 304 · see citing works

Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease☆

Merched, A. J., Xia, Y., Visvikis‐Siest, S., Sérot, J., & Siest, G. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00103-7 · Cited by 273 · see citing works

Structural Basis for Increased Toxicity of Pathological Aβ42:Aβ40 Ratios in Alzheimer Disease

Pauwels, K., Williams, T. L., Morris, K. L., Jonckheere, W., Vandersteen, A., Kelly, G., Schymkowitz, J., Rousseau, F., Pastore, A., Serpell, L. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.264473 · Cited by 253 · see citing works

Uptake and transport of high‐density lipoprotein (HDL) and HDL‐associated α‐tocopherol by an in vitro blood–brain barrier model

Balázs, Z., Panzenboeck, U., Hammer, A., Sovic, A., Quehenberger, O., Malle, E., & Sattler, W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02373.x · Cited by 239 · see citing works

Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms

Attems, J. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1074-9 · Cited by 238 · see citing works

IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid β Peptide by the Blood–Brain Barrier Neonatal Fc Receptor

Deane, R., Sagare, A. P., Hamm, K., Parisi, M., LaRue, B., Guo, H., Wu, Z., Holtzman, D. M., & Zloković, B. V. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3697-05.2005 · Cited by 233 · see citing works

Plasma clusterin and the risk of Alzheimer disease

Schrijvers, E. M. C. (2011) · JAMA · doi:10.1001/jama.2011.381 · Cited by 220 · see citing works

Distinct Early Folding and Aggregation Properties of Alzheimer Amyloid-β Peptides Aβ40 and Aβ42

Chen, Y., & Glabe, C. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602363200 · Cited by 214 · see citing works

Overexpression of Human Apolipoprotein A-I Preserves Cognitive Function and Attenuates Neuroinflammation and Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer Disease

Lewis, T. L., Cao, D., Lu, H., Mans, R. A., Su, Y. R., Jungbauer, L. M., Linton, M. F., Fazio, S., LaDu, M. J., & Li, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127829 · Cited by 210 · see citing works

Characterization of Apolipoprotein J-Alzheimer's Aβ Interaction

Matsubara, E., Frangione, B., & Ghiso, J. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7563 · Cited by 195 · see citing works

Cerebral amyloid angiopathy: An overview

Yamada, M. (2000) · Neuropathology · doi:10.1046/j.1440-1789.2000.00268.x · Cited by 191 · see citing works

Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging

Silverberg, G. D., Messier, A. A., Miller, M. C., Machan, J. T., Majmudar, S. S., Stopa, E. G., Donahue, J. E., & Johanson, C. E. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181f46e25 · Cited by 191 · see citing works

Apolipoprotein J and Alzheimer's amyloid β solubility

Matsubara, E., Soto, C. A., Governale, S., Frangione, B., & Ghiso, J. A. (1996) · Biochemical Journal · doi:10.1042/bj3160671 · Cited by 187 · see citing works

Mouse syngenic in vitro blood–brain barrier model: a new tool to examine inflammatory events in cerebral endothelium

Coisne, C., Dehouck, L., Faveeuw, C., Delplace, Y., Miller, F., Landry, C., Morissette, C., Fénart, L., Cecchelli, R., Tremblay, P. J., et al. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700281 · Cited by 183 · see citing works

Brain Expression of Apolipoproteins E, J, and A‐I in Alzheimer's Disease

Harr, S. D., Uint, L., Hollister, R. D., Hyman, B. T., & Mendez, A. J. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062429.x · Cited by 182 · see citing works

Isoform‐Specific Effects of Apolipoproteins E2, E3, and E4 on Cerebral Capillary Sequestration and Blood‐Brain Barrier Transport of Circulating Alzheimer's Amyloid β

Martel, C. L., Mackic, J. B., Matsubara, E., Governale, S., Miguel, C., Miao, W., McComb, J. G., Frangione, B., Ghiso, J., & Zlokovic, B. V. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69051995.x · Cited by 149 · see citing works

Differences in amyloid-β clearance across mouse and human blood–brain barrier models: Kinetic analysis and mechanistic modeling

Qosa, H., Abuasal, B. S., Romero, I. A., Weksler, B., Couraud, P.-O., Keller, J. N., & Kaddoumi, A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.01.023 · Cited by 146 · see citing works

The Soluble Form of Alzheimer′s Amyloid β Protein Is Complexed to High Density Lipoprotein 3 and Very High Density Lipoprotein in Normal Human Plasma

Koudinov, A. R., Matsubara, E., Frangione, B., & Ghiso, J. A. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2788 · Cited by 141 · see citing works

Apical-to-Basolateral Transport of Amyloid-β Peptides through Blood-Brain Barrier Cells is Mediated by the Receptor for Advanced Glycation End-Products and is Restricted by P-Glycoprotein

Candela, P., Gosselet, F., Saint‐Pol, J., Sevin, E., Boucau, M., Boulanger, É., Cecchelli, R., & Fénart, L. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100462 · Cited by 136 · see citing works

An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening

Culot, M., Lundquist, S., Hallier-Vanuxeem, D., Nion, S., Landry, C., Delplace, Y., Dehouck, M., Bérézowski, V., Fénart, L., & Cecchelli, R. (2008) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.12.016 · Cited by 134 · see citing works

Apolipoprotein A-I Directly Interacts with Amyloid Precursor Protein and Inhibits Aβ Aggregation and Toxicity

Koldamova, R. P., Lefterov, I. M., Lefterova, M. I., & Lazo, J. S. (2001) · Biochemistry · doi:10.1021/bi002186k · Cited by 131 · see citing works

Apolipoprotein A-I Deficiency Increases Cerebral Amyloid Angiopathy and Cognitive Deficits in APP/PS1ΔE9 Mice

Lefterov, I. M., Fitz, N. F., Cronican, A. A., Fogg, A., Lefterov, P., Kodali, R. B., Wetzel, R. B., & Koldamova, R. P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127738 · Cited by 129 · see citing works

Human apolipoprotein A–I binds amyloid-β and prevents Aβ-induced neurotoxicity

Paula-Lima, A. C., Tricerri, M. A., Brito-Moreira, J., Bomfim, T. R., Oliveira, F. F., Magdesian, M. H., Grinberg, L. T., Panizzutti, R., & Ferreira, S. T. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.12.003 · Cited by 121 · see citing works

The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease

ElAli, A., & Rivest, S. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00045 · Cited by 109 · see citing works

Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis.

Wısnıewskı, T., Golabek, A. A., Kida, E., Wisniewski, K. E., & Frangione, B. (1995) · Europe PMC (PubMed Central) · Cited by 107 · see citing works

Alzheimer's amyloid β interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids

Koudinov, A. R., Berezov, T. T., Kumar, A. R., & Koudinova, N. V. (1998) · Clinica Chimica Acta · doi:10.1016/s0009-8981(97)00207-6 · Cited by 102 · see citing works

Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis.

Jeynes, B., & Provias, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508785908937 · Cited by 99 · see citing works

Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood–brain barrier: Use of an in vitro model

Gosselet, F., Candela, P., Sevin, E., Bérézowski, V., Cecchelli, R., & Fénart, L. (2008) · Brain Research · doi:10.1016/j.brainres.2008.10.036 · Cited by 97 · see citing works

The Relation between Apolipoprotein A-I and Dementia: The Honolulu-Asia Aging Study

Saczynski, J. S., White, L. R., Peila, R., Rodríguez, B. L., & Launer, L. J. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm027 · Cited by 92 · see citing works

Intravenously Injected Human Apolipoprotein A‐I Rapidly Enters the Central Nervous System via the Choroid Plexus

Stukas, S. K., Robert, J., Lee, M., Kulić, I., Carr, M., Tourigny, K., Fan, J., Namjoshi, D., Lemke, K., DeValle, N., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001156 · Cited by 91 · see citing works

Cerebral clearance of human amyloid‐β peptide (1–40) across the blood–brain barrier is reduced by self‐aggregation and formation of low‐density lipoprotein receptor‐related protein‐1 ligand complexes

Ito, S., Ohtsuki, S., Kamiie, J., Nezu, Y., & Terasaki, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04938.x · Cited by 85 · see citing works

Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice

Robert, J., Stukas, S. K., Button, E. B., Cheng, W. H., Lee, M., Fan, J., Wilkinson, A., Kulić, I., Wright, S. D., & Wellington, C. L. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.005 · Cited by 77 · see citing works

Expression of Apolipoprotein A‐I in Porcine Brain Endothelium In Vitro

Möckel, B., Zinke, H., Flach, R., Weiß, B., Weiler-Guettler, H., & Gassen, H. G. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62020788.x · Cited by 76 · see citing works

In vitro discrimination of the role of LRP1 at the BBB cellular level: Focus on brain capillary endothelial cells and brain pericytes

Candela, P., Saint‐Pol, J., Kuntz, M., Boucau, M., Lamartinière, Y., Gosselet, F., & Fénart, L. (2014) · Brain Research · doi:10.1016/j.brainres.2014.10.047 · Cited by 71 · see citing works

Amyloid-β Peptides, Alzheimer's Disease and the Blood-brain Barrier

Gosselet, F., Saint‐Pol, J., Candela, P., & Fénart, L. (2013) · Current Alzheimer Research · doi:10.2174/15672050113106660174 · Cited by 70 · see citing works

Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease

Kawano, M., Kawakami, M., Otsuka, M., Yashima, H., Yaginuma, T., & Ueki, A. (1995) · Clinica Chimica Acta · doi:10.1016/0009-8981(95)06115-t · Cited by 68 · see citing works

Brain Pericytes ABCA1 Expression Mediates Cholesterol Efflux but not Cellular Amyloid-β Peptide Accumulation

Saint‐Pol, J., Vandenhaute, E., Boucau, M., Candela, P., Dehouck, L., Cecchelli, R., Dehouck, M., Fénart, L., & Gosselet, F. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-112090 · Cited by 66 · see citing works

Evidence for Transcapillary Transport of Reduced Glutathione in Vascular Perfused Guinea-Pig Brain

Zloković, B. V., Mačkić, J. B., McComb, J. G., Weiss, M. H., Kaplowitz, N., & Kannan, R. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1715 · Cited by 63 · see citing works

Clusterin in neurological disorders: Molecular perspectives and clinical relevance

Charnay, Y., Imhof, A., Vallet, P. G., Kövari, E., Bouras, C., & Giannakopoulos, P. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.05.006 · Cited by 53 · see citing works

Oxysterols decrease apical-to-basolateral transport of Aß peptides via an ABCB1-mediated process in an in vitro Blood-brain barrier model constituted of bovine brain capillary endothelial cells

Saint‐Pol, J., Candela, P., Boucau, M., Fénart, L., & Gosselet, F. (2013) · Brain Research · doi:10.1016/j.brainres.2013.04.008 · Cited by 49 · see citing works

A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier

Bachmeier, C. J., Paris, D., Beaulieu‐Abdelahad, D., Mouzon, B., MULLAN, M. J., & Crawford, F. (2012) · Neurodegenerative Diseases · doi:10.1159/000337231 · Cited by 48 · see citing works

Opposing effects ofApoe/Apoa1double deletion on amyloid-β pathology and cognitive performance in APP mice

Fitz, N. F., Tapias, V., Cronican, A. A., Castranio, E. L., Saleem, M., Carter, A. Y., Lefterova, M. I., Lefterov, I. M., & Koldamova, R. P. (2015) · Brain · doi:10.1093/brain/awv293 · Cited by 37 · see citing works

Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier

Bachmeier, C. J., MULLAN, M. J., & Paris, D. (2010) · Cytotechnology · doi:10.1007/s10616-010-9313-x · Cited by 34 · see citing works

Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies

Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M., & Buckley, N. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00164 · Cited by 381 · see citing works

Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies

Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353 · see citing works

Exercise benefits on Alzheimer’s disease: State-of-the-science

Valenzuela, P. L., Castillo-García, A., Morales, J. S., de la Villa, P., Hampel, H., Emanuele, E., Lista, S., & Lucia, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101108 · Cited by 337 · see citing works

Brain-targeted drug delivery by manipulating protein corona functions

Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11593-z · Cited by 334 · see citing works

Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease

Wang, Q., Huang, X., Su, Y., Yin, G., Wang, S., Yu, B., Li, H., Qi, J., Chen, H., Zeng, W., et al. (2022) · Brain · doi:10.1093/brain/awac236 · Cited by 219 · see citing works

Dysfunction of the blood–brain barrier in Alzheimer's disease: Evidence from human studies

Kurz, C., Walker, L., Rauchmann, B., & Perneczky, R. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12782 · Cited by 183 · see citing works

APOA1: a Protein with Multiple Therapeutic Functions

Cochran, B. J., Ong, K. L., Manandhar, B., & Rye, K. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00906-7 · Cited by 182 · see citing works

Decreased levels of circulating trimethylamine N-oxide alleviate cognitive and pathological deterioration in transgenic mice: a potential therapeutic approach for Alzheimer’s disease

Gao, Q., Wang, Y., Wang, X., Fu, S., Zhang, X., Wang, R., & Zhang, X. (2019) · Aging · doi:10.18632/aging.102352 · Cited by 118 · see citing works

Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood‐brain barrier

Biemans, E. A. L. M., Jäkel, L., de Waal, R. M. W., Kuiperij, H. B., & Verbeek, M. M. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23964 · Cited by 85 · see citing works

The role of amyloid beta clearance in cerebral amyloid angiopathy: more potential therapeutic targets

Qi, X.-M., & Ma, J. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0091-7 · Cited by 81 · see citing works

Regulatory effects of simvastatin and apoJ on APP processing and amyloid-β clearance in blood-brain barrier endothelial cells

Zandl‐Lang, M., Fanaee‐Danesh, E., Sun, Y., Albrecher, N. M., Gali, C. C., Čančar, I., Kober, A. C., Tam‐Amersdorfer, C., Stracke, A., Storck, S. E., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.09.008 · Cited by 71 · see citing works

Apolipoprotein A-I Crosses the Blood-Brain Barrier through Clathrin-Independent and Cholesterol-Mediated Endocytosis

Zhou, A. L., Swaminathan, S. K., Curran, G. L., Poduslo, J. F., Lowe, V. J., Li, L., & Kandimalla, K. K. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254201 · Cited by 63 · see citing works

The Extent of Human Apolipoprotein A-I Lipidation Strongly Affects the β-Amyloid Efflux Across the Blood-Brain Barrier in vitro

Magro, R. D., Simonelli, S., Cox, A., Formicola, B., Corti, R., Cassina, V., Nardo, L., Mantegazza, F., Salerno, D., Grasso, G., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00419 · Cited by 58 · see citing works

HDL Proteome and Alzheimer’s Disease: Evidence of a Link

Marsillach, J., Adorni, M. P., Zimetti, F., Papotti, B., Zuliani, G., & Cervellati, C. (2020) · Antioxidants · doi:10.3390/antiox9121224 · Cited by 57 · see citing works

Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice

de Retana, S. F., Marazuela, P., Solé, M., Colell, G., Bonaterra‐Pastra, A., Sánchez‐Quesada, J. L., Montaner, J., Maspoch, D., Cano‐Sarabia, M., & Hernández‐Guillamón, M. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0498-8 · Cited by 53 · see citing works

Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy

Camacho, J., Moliné, T., Bonaterra‐Pastra, A., y Cajal, S. R., Martínez-Sáez, E. A., & Hernández‐Guillamón, M. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00187 · Cited by 51 · see citing works

Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis

de Retana, S. F., Cano‐Sarabia, M., Marazuela, P., Sánchez‐Quesada, J. L., García‐León, A., Montañola, A., Montaner, J., Maspoch, D., & Hernández‐Guillamón, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15215-w · Cited by 47 · see citing works

ABCA7 Downregulation Modifies Cellular Cholesterol Homeostasis and Decreases Amyloid-β Peptide Efflux in an <i>in vitro</i> Model of the Blood-Brain Barrier

Lamartinière, Y., Boucau, M.-C., Dehouck, L., Krohn, M., Pahnke, J., Candela, P., Gosselet, F., & Fenart, L. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170883 · Cited by 50 · see citing works

Bridging systemic metabolic dysfunction and Alzheimer’s disease: the liver interface

Song, D., Yang, L., Yang, L.-L., Luo, Y., & Yao, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00849-6 · Cited by 53 · see citing works

Association between Serum Concentrations of Apolipoprotein A-I (ApoA-I) and Alzheimer’s Disease: Systematic Review and Meta-Analysis

Zuin, M., Cervellati, C., Trentini, A., Passaro, A., Rosta, V., Zimetti, F., & Zuliani, G. (2021) · Diagnostics · doi:10.3390/diagnostics11060984 · Cited by 45 · see citing works

Intravenous treatment with human recombinant ApoA-I Milano reduces beta amyloid cerebral deposition in the APP23-transgenic mouse model of Alzheimer's disease

de Retana, S. F., Montañola, A., Marazuela, P., Cuesta, M. D. L., Batlle, A., Fatar, M., Grudzenski, S., Montaner, J., & Hernández‐Guillamón, M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.08.028 · Cited by 44 · see citing works

The pleiotropic vasoprotective functions of high density lipoproteins (HDL)

Boyce, G. K., Button, E. B., Sonja, S. V., & Wellington, C. L. (2017) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160103 · Cited by 41 · see citing works

High-density lipoprotein in Alzheimer's disease: From potential biomarkers to therapeutics

Jin, Y., Chifodya, K., Han, G., Jiang, W., Chen, Y., Shi, Y., Xu, Q., Xi, Y., Wang, J., Zhou, J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.018 · Cited by 39 · see citing works

The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer’s Disease

Chernick, D., Zhong, R., & Li, L. (2020) · Biomolecules · doi:10.3390/biom10091276 · Cited by 38 · see citing works

Understanding the Exchange of Systemic HDL Particles Into the Brain and Vascular Cells Has Diagnostic and Therapeutic Implications for Neurodegenerative Diseases

Valkenburgh, J. S. V., Meuret, C. J., Martinez, A. E., Kodancha, V., Solomon, V. A., Chen, K., & Yassine, H. N. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.700847 · Cited by 36 · see citing works

Association of Circulating Apolipoprotein AI Levels in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis

Tong, J., Gong, S., Zhang, Y.-S., Dong, J.-R., Zhong, X., Wei, M., & Liu, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.899175 · Cited by 28 · see citing works

High-Density Lipoprotein Mimetic Peptide 4F Efficiently Crosses the Blood-Brain Barrier and Modulates Amyloid-β Distribution between Brain and Plasma

Swaminathan, S. K., Zhou, A. L., Ahlschwede, K. M., Curran, G. L., Lowe, V. J., Li, L., & Kandimalla, K. K. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265876 · Cited by 22 · see citing works

Evaluation of cerebrospinal fluid (CSF) and interstitial fluid (ISF) mouse proteomes for the validation and description of Alzheimer’s disease biomarkers

Górska, A. M., Santos‐García, I., Eiriz, I., Brüning, T., Nyman, T. A., & Pahnke, J. (2024) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2024.110239 · Cited by 19 · see citing works

Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer’s Disease

Bonaterra‐Pastra, A., de Retana, S. F., Rivas-Urbina, A., Puig, N., Benı́tez, S., Pancorbo, O., Rodríguez‐Luna, D., Pujadas, F., Freijo, M. D. M., Tur, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9010072 · Cited by 18 · see citing works

ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly

Slot, R. E. R., Kester, M. I., van Harten, A. C., Jongbloed, W., Bouwman, F. H., Teunissen, C. E., Scheltens, P., van der Flier, W. M., & Veerhuis, R. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.017 · Cited by 17 · see citing works

Mechanisms of high-density lipoprotein in regulating blood-brain barrier function: insights and implications

Zhu, P., Xiao, L., & Wang, Y. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00721-1 · Cited by 15 · see citing works

HDL Accessory Proteins in Parkinson’s Disease—Focusing on Clusterin (Apolipoprotein J) in Regard to Its Involvement in Pathology and Diagnostics—A Review

Berdowska, I., Matusiewicz, M., & Krzystek‐Korpacka, M. (2022) · Antioxidants · doi:10.3390/antiox11030524 · Cited by 14 · see citing works

Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii

Lan, X., Qin, S., Liu, H., Guo, M., Zhang, Y., Jin, X., Duan, X., Sun, M., Liu, Z., Wang, W., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02373-z · Cited by 15 · see citing works

Knockout of apolipoprotein A‐I decreases parenchymal and vascular β‐amyloid pathology in the Tg2576 mouse model of Alzheimer's disease

Contu, L., Carare, R. O., & Hawkes, C. A. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12556 · Cited by 13 · see citing works

Fibrillar conformation of an apolipoprotein A-I variant involved in amyloidosis and atherosclerosis

Gisonno, R. A., Prieto, E. D., Gorgojo, J. P., Curto, L. M., Rodrı́guez, M. E., Rosu, S. A., Gaddi, G. M., Finarelli, G. S., Cortez, M. F., Schinella, G. R., et al. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129515 · Cited by 10 · see citing works

Models of cerebral amyloid angiopathy-related intracerebral hemorrhage

Vargas-George, S. A., & Dave, K. R. (2022) · Brain Hemorrhages · doi:10.1016/j.hest.2022.05.001 · Cited by 10 · see citing works

Effects of low-intensity ultrasound opening the blood-brain barrier on Alzheimer's disease—a mini review

Zhou, M., Fu, X., Ma, B., Chen, Z., Cheng, Y., Liu, L., Kan, S., Zhao, X., Feng, S., Jiang, Z., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1274642 · Cited by 9 · see citing works

The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy

Bonaterra‐Pastra, A., Solé, M., Lope‐Piedrafita, S., Lucas-Parra, M., Castellote, L., Marazuela, P., Pancorbo, O., Rodríguez‐Luna, D., & Hernández‐Guillamón, M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01541-5 · Cited by 7 · see citing works

Therapeutic effect of human ApoA‐I‐Milano variant in aged transgenic mouse model of Alzheimer's disease

Solé, M., Marazuela, P., Castellote, L., Bonaterra‐Pastra, A., Giménez‐Llort, L., & Hernández‐Guillamón, M. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16065 · Cited by 7 · see citing works

High-Density Lipoprotein Mimetic Peptide 4F Reduces Toxic Amyloid-Beta Exposure to the Blood-Brain Barrier Endothelium in Alzheimer’s Disease Transgenic Mice

Wang, Z., Zhong, R., Curran, G. L., Min, H.-K. P., Lowe, V. J., Li, L., & Kandimalla, K. K. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00633 · Cited by 7 · see citing works

An Alzheimer’s disease-associated common regulatory variant in a PTK2B intron alters microglial function

Bello, E., Long, K. R., Iwama, S., Steer, J., Cooper, S., Alasoo, K., Kumasaka, N., Schwartzentruber, J., Panousis, N. I., & Bassett, A. R. (2026) · iScience · doi:10.1016/j.isci.2026.115688 · Cited by 6 · see citing works

Molecular Simulation of the Binding of Amyloid Beta to Apolipoprotein A-I in High-Density Lipoproteins

Malajczuk, C. J., & Mancera, R. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031380 · Cited by 6 · see citing works

HDL-replacement therapy: From traditional to emerging clinical applications

Sirtori, C. R., Cincotto, G., Castiglione, S., & Pavanello, C. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.02.001 · Cited by 6 · see citing works

Integrating in vitro disease models of the neurovascular unit into discovery and development of neurotherapeutics

Ding, Y., Shusta, E. V., & Palecek, S. P. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100341 · Cited by 6 · see citing works

[Guideline for hyperlipidemia].

Seishima, M. (2003) · PubMed · Cited by 6 · see citing works

Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan

Rostagno, A. A., Calero, M., Holton, J. L., Révész, T., Lashley, T., & Ghiso, J. A. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105452 · Cited by 6 · see citing works

Cognitive Fitness: Harnessing the Strength of Exerkines for Aging and Metabolic Challenges

Saheli, M., Moshrefi, M., Baghalishahi, M., Mohkami, A., Firouzi, Y., Suzuki, K., & Khoramipour, K. (2024) · Sports · doi:10.3390/sports12020057 · Cited by 5 · see citing works

Gene Co-Expression Analysis of Multiple Brain Tissues Reveals Correlation of FAM222A Expression with Multiple Alzheimer’s Disease-Related Genes

Liang, J., LaFleur, B., Hussainy, S., & Perry, G. L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221241 · Cited by 4 · see citing works

Methionine oxidation of clusterin in Alzheimer’s disease and its effect on clusterin’s binding to beta-amyloid

Smith, A. S., Subramanian, J., Doderer, J. J., & Moskovitz, J. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137874 · Cited by 4 · see citing works

Protein profile of mouse endolymph suggests a role in controlling cochlear homeostasis

Fukuda, M., Okanishi, H., Ino, D., Ono, K., Ōta, T., Wakai, E., Sato, T., Ohta, Y., Kikkawa, Y., Inohara, H., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111214 · Cited by 2 · see citing works

Lipoproteins and amyloid vascular disease

Kane, J. P., & Malloy, M. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000364

Estudio de variantes estructurales de ApoA-I y ApoJ recombinantes como aproximación terapéutica en el contexto de la β-amiloidosis cerebral

de Retana, S. F. (2018)

Metabolic signature of the ganglion cell–inner plexiform layer thickness and the risks of mortality and morbidity: a population-based study in UK BiobankPreprint

Yang, S., Yuan, Y., Chen, Y., Zhang, S., Wang, Y., Shang, X., Bulloch, G., Liao, H., Chen, Y., Zhang, L., et al. (2022) · medRxiv · doi:10.1101/2022.09.26.22280334

Unmasking Hidden Systemic Effects of Neurodegenerative Diseases: A Two-Pronged Approach to Biomarker DiscoveryPreprint

Anjo, S. I., Rosado, M., Baldeiras, I., Gomes, A., Pires, D. C. A., Santa, C., Pinto, J., Januário, C., Santana, I. J., Verdelho, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.23.568435

Güncel Biyokimya Çalışmaları VII

Atıcı, Y., Ökten, Z., Kasebi, S., Arıkan, B. S., Erdem, M., Kıran, T. R., Yağız, A. K., Aktolun, B., Demirağcı, Y. G., Kara, H., et al. (2024) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3109

Protein Profile of Mouse Endolymph Extracts its Protective Role in Controlling the Cochlear HomeostasisPreprint

Fukuda, M., Okanishi, H., Ino, D., Ono, K., Ōta, T., Wakai, E., Sato, T., Ohta, Y., Kikkawa, Y., Inohara, H., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4876614

Nanotechnology in Brain Tumors: Neurosurgical Perspectives

Qazvini, H. R. G., Schulte, R. W., Yamamoto, V. N., Bolanos, J. F., Morris, K., Kateb, B., Two, A. M., Gruen, J. P., & Zada, G. (2024) · Springer eBooks · doi:10.1007/978-3-030-80662-0_26

Developing Arterial Drugs: Lessons from the Hepatic Artery and Other Arterial Injections

Baig, A., Gamblin, T. C., Bello, R. J., & Joshi, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-80173-0_12

Additional file 1 of Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii

Lan, X., Qin, S., Liu, H., Guo, M., Zhang, Y., Jin, X., Duan, X., Sun, M., Liu, Z., Wang, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26699807

Additional file 1 of The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy

Bonaterra‐Pastra, A., Solé, M., Lope‐Piedrafita, S., Lucas-Parra, M., Castellote, L., Marazuela, P., Pancorbo, O., Rodríguez‐Luna, D., & Hernández‐Guillamón, M. (2024) · Figshare · doi:10.6084/m9.figshare.26391677

The crosstalk between blood-brain barrier and neural cells: bidirectional regulation of brain function and pathology

Ju, M., Shen, H., Zhang, X., Tian, M., & Zhang, L. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102475

Rôle du transporteur ABCA7 dans les mécanismes de transport du cholestérol et des peptides β-amyloïdes au niveau de la barrière hémato-encéphalique et implications dans la maladie d'Alzheimer

Lamartinière, Y. (2018) · theses.fr (ABES) · doi:10.70675/b0a8ed96zf1a9z474fzbc32z3fac7c6a413f

O3‐06‐06: Modulation of beta‐amyloid(1‐40) peptide and apoa1/apoj transport across a blood‐brain barrier model

Hernández‐Guillamón, M., Merino-Zamorano, C., Montañola, A., de Retana, S. F., Saint‐Pol, J., Gosselet, F., Mysiorek, C., & Montaner, J. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.07.272

Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System

Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow &amp; Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · see citing works

The putative blood-brain barrier transporter for the β-amyloid binding protein apolipoprotein j is saturated at physiological concentrations

Shayo, M., McLay, R. N., Kastin, A. J., & Banks, W. A. (1997) · Life Sciences · doi:10.1016/s0024-3205(96)00685-6 · Cited by 70 · see citing works

A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier

Bachmeier, C. J., Paris, D., Beaulieu‐Abdelahad, D., Mouzon, B., MULLAN, M. J., & Crawford, F. (2012) · Neurodegenerative Diseases · doi:10.1159/000337231 · Cited by 48 · see citing works

Vascular Transport of Alzheimer’s Amyloid β Peptides and Apolipoproteins

Zloković, B. V., Ghiso, J. A., & Frangione, B. (2000) · Springer eBooks · doi:10.1007/978-94-017-1007-7_20 · Cited by 1 · see citing works